NWBO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Apr 2024 @ 15:59):

Stats
Today's Volume	1.18M
Average Volume	1.75M
Market Cap	601.53M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.42
ATR14	$0.00100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-16	Malik Navid	Buy	125 000	Common Stock
2023-11-17	Malik Navid	Buy	150 000	Common Stock
2023-11-17	Malik Navid	Buy	295 000	Common Stock
2023-04-03	Bosch Marnix L	Buy	119 355	Common Stock
2023-04-04	Boynton Alton L	Sell	6 794 191	STOCK OPTIONS

INSIDER POWER
-81.94
Last 96 transactions
Buy: 331 589 317 \| Sell: 61 146 214

Volume Correlation

Long: -0.49 (neutral)

Short: -0.61 (weak negative)

Signal:(55.688) Neutral

Northwest Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Northwest Correlation - Currency/Commodity

-0.12
( neutral )

0.32
( neutral )

0.00
( neutral )

-0.79
( moderate negative )

Northwest Financials

Annual	2023
Revenue:	$1.93M
Gross Profit:	$199 000 (10.30 %)
EPS:	$-0.0559

Q4	2023
Revenue:	$445 000
Gross Profit:	$24 000.00 (5.39 %)
EPS:	$-0.0164

Q3	2023
Revenue:	$406 000
Gross Profit:	$-83 000.00 (-20.44 %)
EPS:	$-0.0168

Q2	2023
Revenue:	$201 000
Gross Profit:	$-220 000 (-109.45 %)
EPS:	$-0.0130

Financial Reports:

No articles found.

Northwest

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.